Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: Results from the International Autoimmune Hepatitis Group.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsThan, Nwe Ni
Wawman, Rebecca E
Appanna, Gautham D
Montano-Loza, Aldo J
Manns, Michael P
Burak, Kelly W
Adams, David H
Hirschfield, Gideon M
Oo, Ye Htun
MetadataShow full item record
AbstractTwenty-two patients with type-1 AIH were included, with a median age of 40 years at diagnosis (range 19-79); 15/22 (68%) were female and 18/22 (82%) were Caucasian. The median period from diagnosis to the end of follow-up in these patients was 11 years (range 3-28). Values of alanine aminotransferase, aspartate aminotransferase and albumin improved significantly following rituximab therapy, and were sustained for up to 2 years (all p ≪0.001). Prednisolone doses were significantly reduced by 12 months post-treatment (p = 0.003), with 13/21 (62%) patients having a dose reduction. Over a median post-treatment follow-up period of 6 years (range 1-10), 5 patients developed AIH flares at a median of 22 months post-treatment, giving an estimated 71% freedom from AIH flare at 2 years. Four of these patients received a second course of treatment, of whom 2 had subsequent further flares. No serious adverse events attributable to rituximab were recorded.
CitationJHEP Rep. 2019 Nov 5;1(6):437-445. doi: 10.1016/j.jhepr.2019.10.005. eCollection 2019 Dec.
AffiliationHZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
- A review of the utility of tacrolimus in the management of adults with autoimmune hepatitis.
- Authors: Hanouneh M, Ritchie MM, Ascha M, Ascha MS, Chedid A, Sanguankeo A, Zein NN, Hanouneh IA
- Issue date: 2019 Jan
- Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy.
- Authors: Than NN, Wiegard C, Weiler-Normann C, Füssel K, Mann J, Hodson J, Hirschfield GM, Lohse AW, Adams DH, Schramm C, Oo YH
- Issue date: 2016 Mar
- Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy.
- Authors: Burak KW, Swain MG, Santodomingo-Garzon T, Lee SS, Urbanski SJ, Aspinall AI, Coffin CS, Myers RP
- Issue date: 2013
- [Clinical and pathological characteristics and outcome of 46 children with autoimmune hepatitis].
- Authors: Cao LL, Zhang M, Zhu SS, Dong Y, Xu ZQ, Chen DW, Wang LM, Wang FC, Gan Y, Yan JG, Wang P, Li AQ
- Issue date: 2019 Jan 2
- Long-term observation of acute-onset autoimmune hepatitis presenting clinically and radiologically as acute hepatitis.
- Authors: Fujiwara K, Fukuda Y, Seza K, Saito M, Yasui S, Nakano M, Yokosuka O, Kato N
- Issue date: 2018 Mar